Combination and sequential therapy for the treatment of Osteoporosis [electronic resource] / Felicia Cosman.
Material type:![Film](/opac-tmpl/lib/famfamfam/VM.png)
- Chemotherapy, Combination
- Osteoporosis -- Chemotherapy
- Osteoporosis -- Treatment
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Bone Density Conservation Agents -- therapeutic use
- Bone Density
- Diphosphonates -- therapeutic use
- Drug Therapy, Combination
- Osteoporosis -- drug therapy
- Raloxifene -- therapeutic use
- Teriparatide -- therapeutic use
Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: Current pharmacologic management of osteoporosis -- Choosing anabolic vs. antiresorptive therapy -- The PaTH trial -- Response to teriparatide (TPTD) -- Evaluating combination and sequential therapy -- Zoledronic acid and daily TPTD study -- DATA trial (TPTD or denosumab monotherapy vs. combination) -- TPTD in naïve vs. treatment experienced women -- TPTD monotherapy vs. combination therapy -- TPTD after prior treatment (bisphosphonate, raloxifene or alendronate) -- Total hip BMD percent changes -- Switch to TPTD in patients on prior denosumab or antiresorptive treatment -- TPTD in treatment experienced (switch vs. add) -- Hip & spine strength and volumetric BMD -- CONFORS trial -- Bone turnover.
Access restricted to subscribers.
Mode of access: World Wide Web.
There are no comments on this title.